{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T07:08:09Z","timestamp":1763536089091,"version":"3.44.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.leukres.2023.107043","type":"journal-article","created":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T02:33:34Z","timestamp":1676428414000},"page":"107043","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Incidence and predisposing factors of infection in patients treated with hypomethylating agents"],"prefix":"10.1016","volume":"127","author":[{"given":"Tugcan Alp","family":"Kirkizlar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onur","family":"Kirkizlar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ufuk","family":"Demirci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aytug","family":"Umut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huseyin","family":"Iflazoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elif Gulsum","family":"Umit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet Muzaffer","family":"Demir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.leukres.2023.107043_bib1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2023.107043_bib2","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.2005.05.4346","article-title":"Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B","volume":"24","author":"Silverman","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2023.107043_bib3","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/ajh.23368","article-title":"Predicting infections in high- risk patients with myelodysplastic syndrome\/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study","volume":"88","author":"Merkel","year":"2013","journal-title":"Am. J. Hematol."},{"issue":"7","key":"10.1016\/j.leukres.2023.107043_bib4","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s00277-017-3001-2","article-title":"A retrospective study evaluating the impact of infectious complications during azacitidine treatment","volume":"96","author":"Schuck","year":"2017","journal-title":"Ann. Hematol."},{"issue":"5","key":"10.1016\/j.leukres.2023.107043_bib5","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1634\/theoncologist.2012-0465","article-title":"Concise drug review:azacitidine and decitabine","volume":"18","author":"Derissen","year":"2013","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.leukres.2023.107043_bib6","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2023.107043_bib7","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1600-0609.2010.01456.x","article-title":"Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine","volume":"85","author":"Santini","year":"2010","journal-title":"Eur. J. Haematol."},{"issue":"8","key":"10.1016\/j.leukres.2023.107043_bib8","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.leukres.2023.107043_bib9","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.3324\/haematol.2012.063420","article-title":"Infections in myelodysplastic syndromes","volume":"97","author":"Toma","year":"2012","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.leukres.2023.107043_bib10","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1182\/blood-2010-06-289280","article-title":"Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine","volume":"117","author":"Itzykson","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2023.107043_bib11","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/cncr.23697","article-title":"Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System","volume":"113","author":"Kantarjian","year":"2008","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.leukres.2023.107043_bib12","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/j.1365-2141.1995.tb05590.x","article-title":"The myelodysplastic syndromes: an analysis of prognostic factors in 226 cases from a single institution","volume":"90","author":"Cunningham","year":"1995","journal-title":"Br. J. Haematol."},{"issue":"11","key":"10.1016\/j.leukres.2023.107043_bib13","first-page":"5","article-title":"Risk of infection in elderly patients with AML and MDS treated with hypomethylating agents","volume":"89","author":"Pagano","year":"2018","journal-title":"Acta Biomed."},{"issue":"14","key":"10.1016\/j.leukres.2023.107043_bib14","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1200\/JCO.2017.77.6211","article-title":"Outpatient management of fever and neutropenia in adults treated for malignancy: american society of clinical oncology and infectious diseases society of america clinical practice guideline update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"30","key":"10.1016\/j.leukres.2023.107043_bib15","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2023.107043_bib16","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2023.107043_bib17","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"10.1016\/j.leukres.2023.107043_bib18","unstructured":"D. Bang, J.F. Piccirillo, The Adult Comorbidity Evaluation-27 (ACE-27) test: a new comorbidity index for patients with cancer. Annual meeting of the American Society of Clinical Oncology, May 20, 2000."},{"key":"10.1016\/j.leukres.2023.107043_bib19","doi-asserted-by":"crossref","unstructured":"D.A. Arber , A. Orazi, R. Hassrjian, J. Thiele, M.J. Borowitz, M.M. Le Beau, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 2016;127(20), pp. 2391\u20132405.","DOI":"10.1182\/blood-2016-03-643544"},{"issue":"12","key":"10.1016\/j.leukres.2023.107043_bib20","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system (IPSS-R) for myelodysplastic syndrome","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2023.107043_bib21","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2023.107043_bib22","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2011.35.6394","article-title":"new comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge","volume":"30","author":"Schanz","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.leukres.2023.107043_bib23","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","article-title":"Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia","volume":"128","author":"Elena","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2023.107043_bib24","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1182\/blood-2018-06-857102","article-title":"Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials","volume":"133","author":"Platzbecker","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2023.107043_bib25","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/cid\/ciq147","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.leukres.2023.107043_bib26","unstructured":"CDC\/NHSN Surveillance Definitions for Specific Types of Infections. https:\/\/www.cdc.gov\/nhsn\/pdfs\/pscmanual\/17pscnosinfdef_current.pdf."},{"key":"10.1016\/j.leukres.2023.107043_bib27","unstructured":"https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf."},{"issue":"6","key":"10.1016\/j.leukres.2023.107043_bib28","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"9","key":"10.1016\/j.leukres.2023.107043_bib29","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.leukres.2023.107043_bib30","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.clml.2013.09.014","article-title":"Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidne as salvage therapy. Implications for primary antifungal prophylaxis","volume":"14","author":"Falantes","year":"2014","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"11","key":"10.1016\/j.leukres.2023.107043_bib31","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1007\/s00277-017-3091-x","article-title":"The impact of antimicrobial prophylaxis in morbidity and infections during azacitidine treatment","volume":"96","author":"Lorenzana","year":"2017","journal-title":"Ann. Hematol."},{"issue":"12","key":"10.1016\/j.leukres.2023.107043_bib32","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1002\/cam4.1231","article-title":"Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen","volume":"6","author":"Ali","year":"2017","journal-title":"Cancer Med."},{"issue":"4","key":"10.1016\/j.leukres.2023.107043_bib33","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/ejh.12595","article-title":"Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia","volume":"96","author":"Voso","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.leukres.2023.107043_bib34","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.leukres.2016.01.014","article-title":"Infections in patients with acute myeloid leukemia treated with low intensity therapeutic regimens: Risk factors and efficacy of antibiotic prophylaxis","volume":"42","author":"Bainschab","year":"2016","journal-title":"Leuk. Res"},{"issue":"10","key":"10.1016\/j.leukres.2023.107043_bib35","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1080\/10428194.2017.1295141","article-title":"Incidence, etiology and timing of infections following azacitidine therapy for myelodysplastic syndromes","volume":"58","author":"Trubiano","year":"2017","journal-title":"Leuk. Lymphoma"},{"issue":"8","key":"10.1016\/j.leukres.2023.107043_bib36","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/myc.12500","article-title":"Invasive fungal infections in AML\/MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis?","volume":"59","author":"Pomares","year":"2016","journal-title":"Mycoses"},{"issue":"2","key":"10.1016\/j.leukres.2023.107043_bib37","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/ejh.12883","article-title":"Infectious complications in patients with myelodysplastic syndromes: a review of the literature with emphasis on patients treated with 5-azacitidine","volume":"99","author":"Radsak","year":"2017","journal-title":"Eur. J. Haematol."},{"issue":"6","key":"10.1016\/j.leukres.2023.107043_bib38","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1016\/j.clml.2015.02.030","article-title":"Higher infection rate after 7- compared with 5-day cycle of azacitidine in patients with higher risk myelodysplastic syndrome","volume":"15","author":"Ofran","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"6","key":"10.1016\/j.leukres.2023.107043_bib39","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/tid.12130","article-title":"Epidemiology and risk factors for infections in myelodysplastic syndromes","volume":"15","author":"Sullivan","year":"2013","journal-title":"Transpl. Infect. Dis."},{"issue":"9","key":"10.1016\/j.leukres.2023.107043_bib40","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.clml.2018.05.017","article-title":"Hypomethylating agents-associated infections- systematic review and meta-analysis of randomized controlled trials","volume":"18","author":"Alon","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"3","key":"10.1016\/j.leukres.2023.107043_bib41","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/bjh.12256","article-title":"Comparative analysis between azacitidne and decitabine for the treatment of myelodysplastic syndromes","volume":"161","author":"Lee","year":"2013","journal-title":"Br. J. Haematol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623000280?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623000280?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:03:11Z","timestamp":1758934991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212623000280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":41,"alternative-id":["S0145212623000280"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107043","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence and predisposing factors of infection in patients treated with hypomethylating agents","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107043"}}